Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Cancer Immunol Immunother. 2016 Sep 30;65(12):1523–1532. doi: 10.1007/s00262-016-1904-8

Table 2.

KIR and KIR-ligand genotype frequency

		Number of patients^a	%

2DL1	+	103	97
2DL1	−	3	3

2DL2	+	52	49
2DL2	−	54	51

2DL3	+	92	87
2DL3	−	14	13

2DL5	+	51	48
2DL5	−	55	52

2DS1	+	35	33
2DS1	−	71	67

2DS2	+	50	48
2DS2	−	56	52

2DS3	+	28	26
2DS3	−	78	74

2DS4	+	102	96
2DS4	−	4	4

2DS5	+	31	29
2DS5	−	75	71

3DL1	+	103	97
3DL1	−	3	3

3DS1	+	32	30
3DS1	−	74	70

HLA-C	C1/C1	37	35
	C1/C2	51	49
	C2/C2	17	16

HLA-Bw4	+	74	70
HLA-Bw4	−	31	30

^a

One of the 107 patients was excluded from KIR analyses; two of the 107 patients were excluded from KIR-ligand analyses.